Recently, Shanghai LKtime Biotechnology Co., Ltd. has reached a strategic cooperation with Shanghai Bio-Pharmaceutical Technology Development Center (hereinafter referred to as "Bio-Med Center"), successfully adding a 2000L mammalian cell expression system production line, which is planned to be put into commercial operation in the third quarter of 2023.

This cooperation with Shanghai Bio-Med Center demonstrates the technological strengths of LKtime Biotech and is a comprehensive recognition of Lingkang Times' overall strength by the Center. The leaders of Bio-Med Center have fully affirmed LKtime Biotech' R&D and production capabilities in the field of biomacromolecules and have expressed their continuous support for the development of LKtime Biotech' development. Through this in-depth cooperation, the synergistic advantage of 1+1>2 will be leveraged to further enhance the service capabilities of Shanghai Bio-Pharmaceutical R&D and Translational Functional Platform, while also expanding the scale of LKtime Biotech' production capacity.

Relying on the abundant pharmaceutical R&D resources of Zhangjiang, the advantage of LKtime Biotech' end-to-end one-stop service from R&D to pilot testing to commercial production will become more and more prominent, which can better help domestic and foreign biopharmaceutical companies accelerate the drug development process.

General Manager of LKtime Biotech, Zhang Lei